Azerbaijan Medical Device Changes: State Registration and the 7-Working-Day Filing Obligation

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Paragraph 1.5 provides that where any change occurs in the information reflected in the documents listed in Parts 3 and 4 for already registered medicinal products, pharmacologically active substances and devices, that change is subject to state registration. The second sentence of paragraph 7.8 goes further: for the national registration of changes to the registration documents of a device, the certificate holder must file with the Ministry of Health within 7 working days.

For devices, the documents listed in Part 4 are the eleven dossier items under paragraphs 4.2.1 to 4.2.11. This means: the name of the manufacturer, evidence of the right of manufacture, evidence of foreign registration, the brief description, labelling and packaging, information on substances with pharmacological activity, biological safety data, sterility data, the declaration of conformity, the QMS certificate, documents on the legal entity status and usability documents for used devices — if the information reflected in any one of them changes, state registration must be carried out.

2. Legal basis

  • Resolution of the Cabinet of Ministers of the Republic of Azerbaijan No. 345 of July 18, 2024, on the Rules for the National Registration of Medicinal Products, Pharmacologically Active Substances and Medical Devices, Their Inclusion in the State Register and the Maintenance of the State Register (entered into force on July 19, 2024; Xalq qəzeti, July 20, 2024, No. 151; Collection of Legislation, 2024, No. 7, Article 906; repealed Resolution No. 108 of July 13, 2007, with effect from July 20, 2024): paragraph 1.5 (changes are subject to state registration), second sentence of paragraph 7.8 (device changes filed within 7 working days), paragraph 7.2 (changes to certificate information result in a new certificate), paragraph 7.7 (changes not affecting certificate information do not result in a new certificate), paragraph 4.2 (eleven dossier items), paragraph 6.16 (state duty payable within 5 working days).
  • Law of the Republic of Azerbaijan on Medicinal Products (Dərman vasitələri haqqında, Law of the Republic of Azerbaijan No. 208-IIIQ, adopted on December 22, 2006, entered into force on February 28, 2007, Collection of Legislation of the Republic of Azerbaijan, 2007, No. 2, Article 70), as amended by Law No. 979-VIQD of July 14, 2023 (which added Articles 1-1 and 9-1 as new provisions, Collection of Legislation, 2023, No. 8, Article 1127): Article 6.10 (registration of changes to registration documents is subject to the state duty), Article 6.4 (changes to the registration documents of medicinal products must be registered, cited for comparison), Article 1-1 (list of provisions applicable to devices).
  • Law of the Republic of Azerbaijan on Administrative Procedure, Article 31 (acceptance and registration of applications) and Article 52 (remedying of deficiencies).

3. Expert insights

Insight 1: Paragraph 1.5 defines a change as a change of information, not a change of the product. The wording covers any change in the information reflected in the documents. The trigger is therefore not limited to modifications of the product design; it also includes a manufacturer changing its name, the reissuance of the QMS certificate, a change of number after renewal of the foreign registration, or a new label design. This is a provision whose coverage far exceeds intuition.

Insight 2: The 7 working days are a mandatory period counted from the date the change occurs. The second sentence of paragraph 7.8 uses must file (müraciət etməlidir), a mandatory formulation, in contrast with the permissive may (edə bilər) for re-registration in the first sentence of the same paragraph. Companies must have an internal mechanism capable of capturing the moment a change occurs, otherwise the deadline will silently run out.

Insight 3: Change registration is also chargeable, with its own 5-working-day payment window. Article 6.10 of the Law lists the national registration of changes to registration documents among the events attracting the state duty, and paragraph 6.16 requires payment within 5 working days of receiving the notification of the authority. Companies with frequent changes should treat this fee as a regular operating cost, not as an unexpected expense.

Insight 4: Paragraph 7.7 offers a route for changes that does not produce a new certificate. Where a change does not affect the information contained in the certificate, the state registration is carried out under the procedure in Part 7 without producing a new certificate. This is the least costly route for changes, and the test is whether the information is printed on the certificate — it can be determined simply by comparing against the fields of Annex 5.

Insight 5: Paragraph 1.5 together with paragraph 11.1.3 creates post-market compliance pressure. Paragraph 11.1.3 lists non-compliance with packaging and labelling requirements that persists after a formal warning by the authority as a ground for suspension of the registration. A company that changes its packaging without registering the change under paragraph 1.5 breaches that provision and may additionally trigger the warning and suspension mechanism of paragraph 11.1.3.

4. Practical recommendations

  1. Build a change-capture checklist: list the eleven dossier items one by one, assign an owner to each and set a review frequency (a quarterly cycle is recommended).
  2. Complete the filing within 7 working days after a change occurs (second sentence of paragraph 7.8), planning internally on a 5-working-day lead.
  3. First use the certificate fields of Annex 5 to determine the route: if the change touches a certificate field, follow paragraph 7.2 and issue a new certificate; if not, follow paragraph 7.7 without a new certificate.
  4. Include the state duty for change registration and the 5-working-day payment window in the annual budget and in the process design.
  5. Give priority to packaging and labelling changes to avoid triggering the warning and suspension procedure of paragraph 11.1.3.
  6. Remember that change registration does not extend the validity of the certificate (paragraph 7.2); re-registration must still be filed separately under paragraph 7.8.

5. Verification checklist

  • □ A change-capture checklist covering the eleven dossier items is in place with named owners.
  • □ A quarterly review frequency and the 7-working-day filing deadline have been set.
  • □ A decision flow on whether certificate fields are affected exists (by comparison with Annex 5).
  • □ The state duty for change registration and the 5-working-day payment window are covered in the annual budget.
  • □ Packaging and labelling changes have been designated as priority items.
  • □ The internal position that change registration does not extend validity has been documented.

Regulatory information verified as of October 30, 2026.

This article was prepared and translated by GRZAN as part of the international medical device registration guide. For professional support with regulatory submissions in Azerbaijan and other jurisdictions, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail